Moreover, carvedilol inhibited Ang II-induced HSC contraction by interfering with the AT1R-mediated RhoA/ROCK2 pathway, which may be one of its molecular mechanisms for reducing portal hypertension. The gene discussed is RHOA; the disease is liver disorder.